We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook dims. Read more here.

Allworth Financial LP lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 53.6% during the fourth quarter, Holdings Channel reports. The firm owned 548 shares of the ...

Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Biogen (BIIB – Research Report) yesterday. The company’s shares closed yesterday at ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as ...